Project description
Securing Europe’s capacity to produce medical radioisotopes
The EU is the major world operator of research reactors and supplier of medical radioisotopes. To ensure the supply of research reactors’ fuels and targets, low-enriched uranium (LEU) is key. Success hinges on technological solutions for converting high-enriched uranium to LEU in research reactors. The EU-funded EU-QUALIFY project will bring together a multidisciplinary team of experts, including fuel designers and manufacturers, reactor operators and researchers, to qualify these fuels and the capability to fabricate these fuels. The findings of this project will ensure the availability of high-performance research reactors in Europe, which produce the majority of medical isotopes.
Objective
One of the biggest challenges for European research reactors is securing their nuclear fuel supply to ensure a sustainment of medical isotopes for Europe and the world. This is particularly true for the few operating High Performance Research Reactors (HPRRs) in Europe, which produce the vast majority of medical isotopes. The obligation to convert them from high to low enriched uranium (LEU) nuclear fuels while keeping similar radioisotopes production ratios makes it necessary to develop higher uranium density fuels. The R&D related to that topic was started in previous EURATOM projects (HERACLES-CP and LEU-FOREvER). The main goal of the EU-QUALIFY project is to qualify such fuels and qualify the capability to fabricate such fuels. This will be done by a multi-disciplinary consortium composed of fuel designers/manufactures, reactor operators, research organizations and a university, namely: SCK CEN, CEA, CERCA, ILL, TUM, and G-INP.
The EU-QUALIFY project will build on previous LEU fuel development work with specific focus on the qualification of three particular types of fuels: the dispersed U-Mo, the monolithic U-Mo and the high-loaded dispersed U3Si2 fuels. This qualification will be accomplished through fabrication and concurrent qualification of pilot manufacturing equipment and processes, irradiation under representative irradiation conditions, post-irradiation examinations, as well as modelling of the in-pile behavior to support LEU conversion safety analyses.
This project will contribute to ensuring the availability of HPPR’s, and thus enhance the security of the EU’s capacity in the production of medical radioisotopes. It will thus contribute to health care through provision of innovative medical radioisotopes necessary for diagnostic and therapy and will support European industry by maintaining access to research reactor irradiation capabilities.
Fields of science
Programme(s)
- H2020-Euratom - Euratom Main Programme
- H2020-Euratom-1. - Indirect actions
Funding Scheme
RIA - Research and Innovation actionCoordinator
1160 Bruxelles / Brussel
Belgium